Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Novartis Pharmaceuticals460 participantsStarted Apr 2026

AVAILABLE

Managed Access Programs for INC424, Ruxolitinib

NCT04745637

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)+4 more

Novartis Pharmaceuticals

Data from ClinicalTrials.govTerms

Filters

Filters

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Managed Access Programs for INC424, Ruxolitinib

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Managed Access Programs for INC424, Ruxolitinib